The North American Neuromodulation Society (NANS) joined several leading medical specialty societies in submitting joint letters to Cigna Healthcare and UnitedHealthcare regarding policies that classify peripheral nerve stimulation (PNS) as investigational for the treatment of chronic pain.
The letters highlight a growing body of clinical evidence demonstrating that PNS is a safe and effective therapy for conditions such as chronic migraine, neuropathic pain, and complex regional pain syndrome.
The societies note that PNS devices are FDA-cleared and supported by Medicare coverage policies, yet some private payer policies continue to restrict access.
NANS and partner organizations are encouraging insurers to review the latest evidence and reconsider policies to ensure patients have access to this minimally invasive treatment option.